Latest Insider Transactions at Finch Therapeutics Group, Inc. (FNCH)
This section provides a real-time view of insider transactions for Finch Therapeutics Group, Inc. (FNCH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Finch Therapeutics Group, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Finch Therapeutics Group, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 07
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Indirect |
383
-1.55%
|
-
|
|
Jun 07
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Direct |
384
-2.1%
|
-
|
|
May 20
2024
|
Jeffery A Smisek |
SELL
Bona fide gift
|
Indirect |
3,750
-100.0%
|
-
|
|
Mar 28
2024
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Indirect |
1,600
-19.72%
|
$3,200
$2.61 P/Share
|
|
Mar 28
2024
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Direct |
6,642
-100.0%
|
$13,284
$2.57 P/Share
|
|
Nov 22
2023
|
Jeffery A Smisek |
SELL
Open market or private sale
|
Direct |
1,470
-18.12%
|
$4,410
$3.64 P/Share
|
|
Jun 09
2023
|
Susan E Graf Director |
BUY
Open market or private purchase
|
Direct |
5,010
+50.0%
|
$0
$0.27 P/Share
|
|
Feb 21
2023
|
Marc Blaustein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
4,619
-14.16%
|
$0
$0.38 P/Share
|
|
Oct 21
2022
|
Marc Blaustein Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
3,636
-10.03%
|
$3,636
$1.39 P/Share
|
|
Oct 21
2022
|
Joseph Vittiglio Chief Business & Legal Officer |
SELL
Open market or private sale
|
Direct |
3,636
-10.39%
|
$3,636
$1.39 P/Share
|
|
Jun 13
2022
|
Joseph Vittiglio Chief Business & Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+50.0%
|
-
|
|
Jun 13
2022
|
Marc Blaustein Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
35,000
+49.12%
|
-
|
|
Dec 20
2021
|
Nicholas Haft Director |
BUY
Open market or private purchase
|
Indirect |
63,850
+1.55%
|
$638,500
$10.18 P/Share
|
|
Mar 23
2021
|
Crestovo Investor LLC Director |
BUY
Open market or private purchase
|
Direct |
735,294
+5.5%
|
$12,499,998
$17.0 P/Share
|
|
Mar 23
2021
|
Crestovo Investor LLC Director |
BUY
Conversion of derivative security
|
Direct |
11,906,147
+50.0%
|
-
|
|
Mar 23
2021
|
Domenic J Ferrante Director |
BUY
Open market or private purchase
|
Indirect |
102,941
+13.93%
|
$1,749,997
$17.0 P/Share
|
|
Mar 23
2021
|
Domenic J Ferrante Director |
BUY
Conversion of derivative security
|
Indirect |
533,254
+34.98%
|
-
|
|
Mar 23
2021
|
Nicholas Haft Director |
BUY
Open market or private purchase
|
Indirect |
882,351
+50.0%
|
$14,999,967
$17.0 P/Share
|
|
Mar 23
2021
|
Nicholas Haft Director |
BUY
Conversion of derivative security
|
Indirect |
3,110,706
+45.06%
|
-
|
|
Mar 23
2021
|
Jeffery A Smisek |
BUY
Open market or private purchase
|
Indirect |
88,235
+4.95%
|
$1,499,995
$17.0 P/Share
|
|
Mar 23
2021
|
Jeffery A Smisek |
BUY
Conversion of derivative security
|
Indirect |
1,606,306
+23.69%
|
-
|